Key clinical point : Aumolertinib vs. gefitinib as the first-line therapy significantly improves progression-free survival (PFS) in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) and epidermal growth factor receptor ( EGFR) mutation (i.e., exon 19 deletion or L858R mutation).
Major finding : The aumolertinib vs. gefitinib group had a significantly longer median PFS (19.3 vs. 9.9 months; hazard ratio [HR] 0.46; P < .0001). The PFS advantage of aumolertinib over gefitinib was substantial in the subgroup of patients with central nervous system metastases (15.3 vs. 8.2 months; HR 0.38; P < .0001).
Study details : This randomized, double-blind, multicenter, phase 3 AENEAS trial included 429 patients with EGFR-mutated NSCLC who were randomly assigned (1:1) to receive either the first-line aumolertinib or gefitinib once daily orally.
Disclosures: The study was funded by Hansoh Pharmaceutical Group Co, Ltd. Many authors reported ties with one or more pharmaceutical companies, including Hansoh Pharma.
Source: Lu S et al. AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non–small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 (May 17). Doi: 10.1200/JCO.21.02641